BioNTech SE has announced promising results from its global Phase 2 ROSETTA Lung-107 clinical trial, which evaluates pumitamig, an investigational bispecific immunomodulator, for treating metastatic non-small cell lung cancer (NSCLC). This development is significant as it showcases BioNTech's ongoing commitment to addressing critical unmet needs in cancer therapy, particularly for patients whose disease has progressed after initial treatments.

On October 25, 2026, BioNTech (Nasdaq: BNTX) and Bristol Myers Squibb Company (NYSE: BMY) released the first data from the ROSETTA Lung-107 trial. The study focuses on the combination of pumitamig and docetaxel for patients with NSCLC who have seen their disease worsen after prior immunotherapy and chemotherapy.

Background

BioNTech SE is a leading biopharmaceutical company based in Mainz, Germany, specializing in developing innovative therapies for cancer and other serious diseases. The company operates under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products (no diagnostic substances). BioNTech trades on the Nasdaq under the ticker BNTX.

Recent filings include multiple 6-K forms, with the latest submission made on October 26, 2026, detailing the trial results and ongoing developments.

What the Filing Says

The SEC filing indicates that the ROSETTA Lung-107 trial demonstrated encouraging responses in both squamous and non-squamous NSCLC. The confirmed objective response rate was reported at 36.7%, with an early median progression-free survival of 6.9 months. The filing highlights a significant unmet need for patients who have progressed on standard treatments, where the average progression-free survival is typically below four months.

Impact

The results from this trial may significantly impact patients with advanced lung cancer, particularly those who have limited treatment options after standard care. The collaboration with Bristol Myers Squibb further underscores the competitive landscape in the oncology sector, as both companies aim to enhance treatment outcomes for patients facing aggressive cancers.

What's Next

The filing does not specify the next steps following this announcement, but the positive results from the ROSETTA Lung-107 trial may lead to further investigations and potential regulatory submissions for pumitamig in treating NSCLC.